ArticleLiver international : official journal of the International Association for the Study of the Liver2026
Sex Disparities in Hepatitis C Treatment Initiation: Role of Universal Access to DAA in France (ANRS FANTASIO 2).
Article in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sex Disparities in Hepatitis C Treatment Initiation: Role of Universal Access to DAA in France (ANRS FANTASIO 2).Liver international : official journal of the International Association for the Study of the Liver · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
BACKGROUND AND
aimsEnsuring access to direct-acting antivirals (DAA) for all individuals concerned is a priority in hepatitis C elimination efforts. We analysed sex disparities in DAA initiation in France over a 9-year period spanning before and after August 2017, when the country implemented universal DAA access.
methodsWe used data from the French National Health Data System for two periods: 2014-2017 and 2017-2022. Socioeconomic and clinical characteristics of adults identified with chronic hepatitis C and residing in metropolitan France were described at each period entry date. DAA initiation incidence rates were then estimated and multivariable Cox proportional hazards models were used to identify potential sex disparities for each period.
resultsThe study population comprised 97 817 and 98 020 individuals (61.3% and 62.0% men) before and after universal access to DAA, respectively. Comorbidity prevalence was significantly lower among women, except for psychiatric disorders. Compared with men, the incidence rate of DAA initiation was lower in women before universal access (24.5 [24.2-24.9] vs. 26.1 [25.8-26.3] per 100 person-years (PY), p < 0.001), and higher after (22.3 [21.9-22.6] vs. 18.5 [18.3-18.7] per 100 PY, p < 0.001). These differences were confirmed in multivariable models.
conclusionsIn France, universal DAA access has reversed sex disparity in treatment initiation among people with chronic hepatitis C. This reversal likely reflects differences in disease progression profiles between men and women. To ensure truly equitable access to HCV care, current research should explore whether reversal or reduction of sex disparities is observed in other countries and subpopulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.